The proteostasis network plays a vital role in maintaining cellular health, particularly in astrocytes, which are significantly impacted by aging and neurodegenerative diseases.

Astrocytes, which make up 20-40% of all glial cells in the human neocortex, are a diverse population in the central nervous system, showcasing both morphological and functional heterogeneity.

Research has shown that alterations in astrocytic properties can disrupt synaptic function, contributing to the progression of neurodegenerative diseases.

Compromised autophagy is a critical factor in various neurodegenerative diseases, underscoring the need for effective therapeutic interventions.

Protein production within cells is susceptible to errors, leading to misfolding and aggregation, a problem that worsens with aging and disease.

The proper functioning of brain circuits depends on the regulation of molecular entities and signaling pathways, with disruptions linked to healthy brain aging.

The dopamine receptor agonist pramipexole has demonstrated potential in modulating neuroinflammation and enhancing autophagy in astrocytes, particularly in a mouse model of Parkinson's Disease.

Treatment with pramipexole resulted in reduced loss of dopamine neurons and decreased activation of astrocytes, indicating a dose-dependent effect on autophagy activity through the dopamine receptor D3.